Clinical Trial Update: PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for PTG-300 in polycythemia vera with elevated hematocrit has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polycythemia Vera

Drugs mentioned

• PTG-300

Snippet

Sponsor: Protagonist Therapeutics, Inc. | Conditions: Polycythemia Vera | Phase 2 | Status: COMPLETED